GuideMe

Sep 6, 2023

September 6, 2023 In a groundbreaking development for renal disease patients, Fresenius Medical Care, the global leader in renal disease care, has recently received FDA 510(k) clearance for its Versi®HD with GuideMe Software. This innovative technology represents a significant step forward in the field of chronic home hemodialysis (HHD) systems and promises to enhance the lives of both patients and healthcare providers. With over 30 million patients treated at home over nearly two decades, Fresenius Medical Care's NxStage has been a pioneer in HHD. The Versi®HD with GuideMe Software aims to build upon this legacy by offering a completely redesigned, self-guided interface that streamlines the HHD experience. Become a Subscriber One of the standout features of this system is its graphical walk-through advice, which assists both patients and nurses in using the technology effectively. This tool not only accelerates patient training but also simplifies the transition to home-based care, making it more accessible and user-friendly for newcomers. Dr. Katarzyna Mazur-Hofsäß, the CEO of Care Enablement at Fresenius Medical Care, expressed enthusiasm about this development, saying, "We challenge the standard of home dialysis with industry-leading products to improve dialysis patients' health and well-being." With this technology, Fresenius Medical Care is setting a new benchmark for home hemodialysis, ensuring that patients receive the support they need for successful therapy at home. The desire to enhance the lives of people with renal disease and patient feedback have both fueled NxStage's long history of innovation. From the introduction of the first portable HHD machine, NxStage System OneTM, to advancements like the PureFlowTM DI Water Purification System and the HHD Connected Health platform Nx2me, Fresenius Medical Care has consistently pushed the boundaries of what is possible in home hemodialysis. Versi®HD with GuideMe Software is the latest evolution of this commitment to innovation, offering a touchscreen interface that further simplifies the HHD experience. Brigitte Schiller, Senior Vice President and Medical Officer for Home Therapies at Fresenius Medical Care, believes that this software improvement will provide much-needed support and confidence to patients and their care partners. "Versi®HD with GuideMe Software will help Fresenius Medical Care expand home therapy access," she stated. This expansion is a crucial step in providing more renal disease patients with the option to receive life-sustaining treatment in the comfort of their homes. In its journey to combat renal disease, Fresenius Medical Care continues to leverage innovation and cutting-edge technology to make a meaningful impact on the lives of those it serves.